Senate Health Committees Face Turnover as Midterms Reshape Digital Health Policy

Senate Republicans face significant turnover on the two committees that shape health policy. STAT reported on 1 October that the finance committee could lose five or more of its 14 Republican members to retirement or competitive races. The health committee faces its own churn. The story, by Washington correspondent John Wilkerson, is behind a STAT+ paywall, but the headline figure is clear: at least five Republicans on finance are set to leave.

That matters for digital health. The committees write the budgets and rules that fund research agencies and shape Medicare coverage decisions.

New members and new priorities can slow or accelerate programs supporting wearable studies, remote monitoring pilots and AI diagnostics. STAT did not name the departing senators in the free portion of the article. The full list sits behind the paywall. What is visible is the scale: five or more out of 14. When those committees change hands, the pipeline of research grants and coverage decisions can shift with them. STAT notes that if Democrats take control of the Senate, they would run the committees, though Republican membership changes could still influence the panels' directions. The midterms decide not just who chairs, but who sits on the panels that write the fine print.

Why the Senate matters for wearable research

The finance committee handles Medicare and Medicaid, which together cover a large share of patients using remote monitoring and wearable devices. The health committee oversees the National Institutes of Health, the Food and Drug Administration and the Centers for Disease Control and Prevention. These agencies fund and regulate clinical studies of digital health tools. The timing is awkward for anyone waiting on federal action. Several digital health policy questions remain open, including how Medicare pays for remote patient monitoring and whether wearable data can be used in clinical trials without extra regulatory hurdles. STAT's related coverage lists drug pricing, Medicaid and research funding as the key policy issues at stake in the midterms.

Private money fills the gap, for now

While Washington sorts out its committees, private investors are pushing ahead with wearable and body-scanning ventures. TechCrunch reported on 30 September that Neko Health, the body-scanning startup co-founded by Spotify's Daniel Ek, raised $700 million to build a business around scanning the human body. The company is not alone. TechCrunch notes that Midjourney is building its own body scanner, and Function Health has raised significant capital for a preventative-health platform.

On the TechCrunch Equity podcast, Dominic-Madori Davis spoke with Farooq Abbasi, founder and general partner of Preface Ventures and an investor in Neko Health. They discussed how Neko compares with other consumer-health startups. The episode, published on 30 September, runs about 30 minutes. The question in the title is blunt: is Neko Health's body scan worth it? The answer depends on what has to happen for body scanning to become part of the broader healthcare system, not just a premium service for the wealthy.

That is where the Senate committees come back in. A scan that costs hundreds of dollars and is not covered by insurance stays a niche product. If Medicare or private insurers start paying for preventative scans, the market changes. The committees that write coverage rules sit upstream of the business models that venture capitalists are funding.

China's health tech surge, and the caveats

The global picture is wider than the United States. Rest of World published an interview on 24 September with Ruby Wang, a physician and consultant who has worked in health tech in China and elsewhere. Wang is the author of an upcoming book, China Cure: The Rise of a Biotech, AI Medicine, and Global Health Superpower.

Wang told Rest of World that China's digital health infrastructure is different in kind from the West's. "In the U.K. and in the U.S., tech is always an add-on in the health system," she said. "You are trying to screw an extra bit onto a rusty machine, whereas in China, because the infrastructure and the digital rails are so technologically enabled, society accepts that as normal."

She also pointed to China's biotech momentum. More clinical trials are being conducted in China than in the U.S., and China now accounts for half of global drug licensing deals, according to Rest of World. Wang said China's share of global drug out-licensing deals could reach 60% this year. She cited Akeso's cancer drug and licensing deals by Pfizer with 3SBio and Innovent Biologics as evidence of what she calls a "DeepSeek moment" in biotech.

But Wang listed caveats. China is strongest in oncology and less mature in immunology, she said. Chinese biotech companies are weak at commercializing their own drugs. That is why out-licensing is so common: a Chinese company signs with Pfizer, and Pfizer sells the drug in the U.S. Wang also warned that security-focused language around Chinese medicine could slow collaboration. "According to World Trade Organization agreements, medicines ethically and legally should not be subject to tariffs because access to them is a human right," she told Rest of World. "But somehow they have been."

Discs, licenses and the ownership question

Away from health policy, the same tension between access and ownership is playing out in video games. Tom's Hardware reported on 30 September that Xbox has rolled out its Disc to Digital feature to all Xbox players. The feature lets owners of eligible physical discs secure a digital license tied to their Xbox profile, so they can play without inserting the disc. Xbox Series X and Xbox One players can use it, though not all titles are eligible and eligibility may change.

There is a catch. "You also need to have access to the qualifying disc to retain the digital license," Tom's Hardware reported. "If you lose, sell, or give away the eligible title, your digital license may be limited or revoked." The feature had been tested with Xbox Insiders since late August and in earlier experiments since July.

The context is Sony's decision to stop manufacturing physical media for new releases by January 2028. A Change.org petition to reverse that decision reached more than 200,000 signatures a week after the announcement, according to Tom's Hardware. Sony has doubled down, saying it will move forward cautiously. Xbox, by contrast, is taking a hybrid path. Former Xbox CEO Phil Spencer said a couple of years ago that the company would not abandon physical media despite the success of Game Pass. Tom's Hardware notes that this move shows its commitment to that promise, even though Spencer has since retired.

A local-first pitch for personal data

One more thread touches the same debate about who controls health and personal data. A project called Omnesis appeared on Hacker News on 28 September, pitched as a private knowledge layer for AI agents. According to its site, Omnesis syncs data from more than 40 sources, including email, messages, notes, calendar, health records and files, into a single local store on hardware the user controls.

The site says the index can be encrypted at rest and that cloud inference is off by default. Embedding, OCR, audio transcription and the built-in agent can each run locally or call a cloud model. The built-in agent, per the site, has no other tools and no internet access. External agents such as Claude or ChatGPT can be pointed at Omnesis through an agent-to-agent protocol, with a policy layer that decides what can be shared or when approval is required.

That is a pitch, not a peer-reviewed study, and the site is the only source for its claims. It is the same argument that wearable makers and health systems are having: if the data is sensitive, where does it live, and who can query it? For now, the answer in Washington depends on committees that are about to change.

STAT's reporting suggests the finance committee could see five or more Republican departures, and the health committee is in flux too. The practical effect for digital health research will not be clear until the new Congress is seated. The direction of travel, more private capital and less certainty about federal funding, is already visible in the deals and products launched in the last week of September.